The FDA requested the withdrawal of Belviq because of 0.6% added risk, but mobile phones are fine.
FDA requests the withdrawal (14 Jan 2020) of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. The order was issued after a study found that 7.7% of the 462 people who used this drug got cancer, while in the control group of 423, only 7.1% did (after five years of use, out of 12000 useds). At the same time the FDA concludes that 135 studies from last decade, some of which find…